Notes
lymphomas, CKD, chronic kidney disease, Stroke
LEUKEMIAS, MYOCARDIAL INFARCTION, STROKE, SOLID TUMORS, LYMPHOMAS
This work was supported by the National Natural Science Foundation of China (82000691); the Science and Technology Planning Project of Guangzhou, China (202102021155); and the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University (2019J004).Author disclosures: Dr. Youbao Li reports grants from the National Natural Science Foundation of China, the Science and Technology Planning Project of Guangzhou, China, and the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University. All other authors report no conflicts of interest.The funders had no role in the design and conduct of the study (data collection, management, analysis, and interpretation), the preparation, review, approval of the manuscript, or the decision to submit the manuscript for publication. This work was supported by the National Natural Science Foundation of China [82000691]; the Science and Technology Planning Project of Guangzhou, China [202102021155]; and the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University [2019J004].Supplemental Figure 1 and Supplemental Tables 1 and 2 are available from the “Supplementary data” link in the online posting of the article and from the same link in the online table of contents at Abbreviations used: BP, blood pressure; CKD, chronic kidney disease; CSPPT, China Stroke Primary Prevention Trial; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; ICP-MS, inductively coupled plasma mass spectrometry; LL, leukemias and lymphomas; MI, myocardial infarction; MTHFR, methylenetetrahydrofolate reductase; SBP, systolic blood pressure; Se, selenium; ST, solid tumors; TC, total cholesterol; tHcy, total homocysteine.